Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.

Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33404258

about

Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends Current systemic treatment of hepatocellular carcinoma: A review of the literature Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update Hepatotoxicity of targeted therapy for cancer.Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development.Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management.Clinical trials in hepatocellular carcinoma: an update.Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition.Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis.Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future.Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.Glycine inhibits angiogenic signaling in human hepatocellular carcinoma cells.Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular Carcinoma.mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy.Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy.The role of mTOR inhibitors in the treatment of hepatocellular carcinoma.The benefit of everolimus in recurrent/epithelioid angiosarcoma patients: Case reports and literature review.A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913.

P2860

Q26830194-0C15B8F5-D377-4C09-90AE-F6F1F966A8A2 Q27026036-B96D83DF-9FCD-4070-856E-559480F64694 Q28067598-A5A22896-E801-4DCA-B1BD-A594BA60BED6 Q30250288-F89CBC1A-2E44-46F0-BDC0-7830983786AD Q30391932-5D5956BA-995E-4C89-A1DE-116DA442C4ED Q33408116-50BF1A16-A6F2-4D63-8AD3-0609766FD999 Q33422744-F0F7B009-2038-4350-838C-83E392EBD821 Q35806395-F8B84A93-20D4-4BCD-B610-896F68FFC87B Q36126047-514EE3C2-5929-4A2F-A78B-BF36104F839D Q36245362-35D37ADA-B90B-4C67-A195-0B322F42A7E2 Q37435638-1013F70F-C169-46A7-8C00-71F8A5CE4ECA Q38155511-20C637DF-4AA3-4BE2-AAED-E135E6F82B3E Q38160838-B775F0EE-6498-46AC-BC07-694EC215494E Q38174585-B226E12A-787D-4A62-B13C-E169F68932E2 Q38176862-8A59B13B-B4B3-40E4-AF87-54912859EA57 Q38212573-30C68151-7640-4155-8357-754725B53B9E Q38554626-085788C8-7EC0-4F3D-8C11-DC66F56C4F35 Q38804626-3D391A59-4760-43D8-B729-E30D582C6698 Q39037350-F2304B1C-25CD-4DC3-A0C7-825A3E9B9788 Q39134670-3800378E-3C86-428F-8E6D-A3A81379BDAC Q41233635-54882FD3-9C33-48F1-AA76-65DC6E1801B6 Q41547474-EA326DCA-551A-4863-B1CC-1A35EFEA760D Q42053469-584159FE-9E59-4946-9EAC-44A08DE3E0A3 Q45848255-D6AFFBCA-29C9-436E-82C8-43F394911C60 Q47155916-A6D37825-D8A6-4DD2-AA5B-1A647BE0F611 Q50068283-48B8367B-6ABE-4B8B-A0CE-4DC623A19BF1

P2860

Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33404258

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Randomised clinical trial: com ...... nced hepatocellular carcinoma.

@ast

Randomised clinical trial: com ...... nced hepatocellular carcinoma.

@en

type

label

Randomised clinical trial: com ...... nced hepatocellular carcinoma.

@ast

Randomised clinical trial: com ...... nced hepatocellular carcinoma.

@en

prefLabel

Randomised clinical trial: com ...... nced hepatocellular carcinoma.

@ast

Randomised clinical trial: com ...... nced hepatocellular carcinoma.

@en

P1433

Q33404258-E59735F2-AFBA-4B12-8453-9B92FAD02358

P1476

Q33404258-EE9D2C75-E2E7-4FA2-886E-1A2903FE627C

P2093

Q33404258-0808D3A7-F9D4-4942-8FFE-4BE11DA4AFBC

Q33404258-0FE5647B-C31A-494B-8E0A-15AEA3CF3A37

Q33404258-31514DC0-9AAD-4094-A143-65ABC86730AA

Q33404258-59977DA4-4CC0-4C13-B1B0-4B6E644911FE

Q33404258-64ED3BD1-CD9A-4799-9430-3A813B30DFD7

Q33404258-B7694837-B019-4F2D-B19F-8AF1DCB38242

Q33404258-B95F6A70-6E65-4DC1-BFEB-165E777364C7

Q33404258-F08240B7-687D-4343-8FE3-058EEAC92056

Q33404258-F8B190EA-886D-41DC-B67E-A11D105A26D0

P2860

Q33404258-08C236EF-3800-4686-BA4D-761B0B0F8123

Q33404258-13A6DE53-8614-48F5-A7CB-36F7B41EFCBB

Q33404258-1D8128C3-B694-40B5-AAF8-5E0FF085B6F3

Q33404258-2002D8A5-BFCC-4EC3-BFD7-BB91EEDE5079

Q33404258-23207C15-B1C3-4C6A-ABB6-AF3BD6A836BA

Q33404258-29398AEC-FA77-41C9-8706-2BCF2D160FA3

Q33404258-30BB56D7-CB54-4EFF-823A-E7796124BAD9

Q33404258-3487BD6C-ED35-4719-A80D-F422B6365A1E

Q33404258-34ABD76D-B1A6-4904-994B-90D67520A204

Q33404258-3C6F74BF-804E-4695-A54D-50F88201CFFF

P304

Q33404258-271446B2-13FC-4292-9FEE-1BAA16439E98

P31

Q33404258-175DD1E9-4DE9-4A06-8883-4B2E08670F53

P356

Q33404258-A7CFFC65-F726-4B95-9832-1601FBB8C64D

P407

Q33404258-750BFE7F-5AA6-418C-9BB8-820981A0BBD7

P433

Q33404258-CF7C5420-8D39-4418-B120-82BE69BA5A48

P478

Q33404258-8FC19275-5BC7-4FB1-B112-1572836538A8

P50

Q33404258-6923D04E-5B12-458A-99FE-EE176D164A35

Q33404258-FCCC4B78-09DB-4AB5-B5C4-C471BE5B34F0

P577

Q33404258-8AADD534-3F7F-4DA7-B524-1DB4A4F0B771

P5875

Q33404258-D80408B9-C57A-4DD1-B0B9-5152056963BC

P698

Q33404258-86BD1169-D790-40E7-99B6-C9BFAA060614

P356

P1433

Alimentary Pharmacology & Therapeutics

P1476

Randomised clinical trial: com ...... anced hepatocellular carcinoma

@en

P2093

C-Y Chen

http://www.w3.org/2001/XMLSchema#string

C-Y Dai

http://www.w3.org/2001/XMLSchema#string

H-S Shiah

http://www.w3.org/2001/XMLSchema#string

J Whang-Peng

http://www.w3.org/2001/XMLSchema#string

J-D Huang

http://www.w3.org/2001/XMLSchema#string

J-Y Chang

http://www.w3.org/2001/XMLSchema#string

L-T Chen

http://www.w3.org/2001/XMLSchema#string

P-W Lin

http://www.w3.org/2001/XMLSchema#string

Y-J Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of Hepatitis B Virus Replication by the Phosphatidylinositol 3-Kinase-Akt Signal Transduction Pathway

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Hepatocellular carcinoma

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Pilot study: rapamycin in advanced hepatocellular carcinoma.

P304

62-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/APT.12132

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233327610

http://www.w3.org/2001/XMLSchema#string

P698

23134470

http://www.w3.org/2001/XMLSchema#string